Cost-effectiveness analysis of annual trichomonas vaginalis screening and treatment in HIV-positive women to prevent HIV transmission

Sexually Transmitted Diseases

Volumn 41, Issue 6, 2014, Pages 353-358

  Lazenby, Gweneth Bratton ^a   Unal, Elizabeth Ramsey ^b   Andrews, Annie Lintzenich ^a   Simpson, Kit ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; SCREENING TEST; SENSITIVITY ANALYSIS; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; ADULT; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; EPIDEMIOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; MASS SCREENING; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; TRANSMISSION; TRICHOMONAS VAGINITIS; UNITED STATES;

ANTIINFECTIVE AGENT; METRONIDAZOLE;

ADULT; ANTI-INFECTIVE AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MASS SCREENING; METRONIDAZOLE; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS; UNITED STATES;

EID: 84901285790     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000008     Document Type: Article

References (30)

1. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002; 34: 1406-1411.
2. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommend Rep 2010; 59:1-110.
3. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000; 27:284-288.
4. Miller MR, Nyirjesy P. Refractory trichomoniasis in HIV-positive and HIV-negative subjects. Curr infect Dis Rep 2011; 13:595-603.
5. Gatski M, Mena L, Levison J, et al. Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among human immunodeficiency virusYinfected women. Sex Transm Dis 2010; 37:502-505.
6. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698-702.
7. Laga M, Nzila N, Goeman J. The interrelationship of sexually transmitted diseases and HIV infection: implications for the control of both epidemics in Africa. AIDS 1991; 5(suppl 1):S55YS63.
8. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358:1593-1601.
9. Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis 2004; 31:547-551.
10. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1 J Infect Dis 2001; 183:1017-1022.
11. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex TransmDis 2009; 36:11-16.
12. Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev 2004; 17:794-803. Table of contents.
13. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009; 200:188 e1-7.
14. Wendel KA, Erbelding EJ, Gaydos CA, et al. Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. Clin Infect Dis 2002; 35:576-580.
15. Huppert JS, Batteiger BE, Braslins P, et al. Use of an immunochromatographic assay for rapid detection of Trichomonas vaginalis in vaginal specimens. J Clin Microbiol 2005; 43:684-687.
16. Cu-Uvin S, Hogan JW,Warren D, et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)Yseropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group. Clin Infect Dis 1999; 29:1145-1150.
17. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:565-571.
18. Staff PE. Medical Fees in the United States: Nationwide Charges for Medicine, Surgery, Laboratory, Radiology, and Allied Health Services. Los Angeles, CA: Practice Management Information Corporation; 2008;1.
19. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: Systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118-129.
20. Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis 2010; 37:392-396.
21. Sorvillo F, Smith L, Kerndt P, et al. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis 2001; 7:927-932.
22. Van der Pol B. Trichomonas vaginalis infection: The most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin Infect Dis 2007; 44:23-25.
23. Baggaley RF, White RG, Hollingsworth TD, et al. Heterosexual HIV-1 infectiousness and antiretroviral use: Systematic review of prospective studies of discordant couples. Epidemiology 2013; 24:110-121.
24. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: A systematic review and meta-analysis. AIDS 2000; 14:2361-2370.
25. Vital signs: HIV prevention through care and treatmentVUnited States. MMWR Morb Mortal Wkly Rep 2011; 60:1618-1623.
26. Radonjic IV, Dzamic AM, Mitrovic SM, et al. Diagnosis of Trichomonas vaginalis infection: The sensitivities and specificities of microscopy, culture and PCR assay. Eur J Obstet Gynecol Reprod Biol 2006; 126:116-120.
27. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PloS One 2011; 6:e17502.
28. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS 2010; 24:2705-2715.
29. Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008; 46:994-999.
30. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: Results from a cohort study. AIDS 1993; 7:95-102.